Orthocell
Orthocell is a leader in the regenerative medicine sector, focusing on innovative treatments for chronic degenerative diseases and injuries. The company specializes in developing collagen medical devices and cell therapies that leverage the body's natural repair mechanisms. Orthocell's products are designed to enhance surgical repair and promote tissue regeneration, positioning it as a pioneer in the biotechnology and life sciences industry.
Short position
Orthocell (ASX:OCC) has 0.03% of its shares on issue reported as short positions as of 5 Oct 2026, or about 69,327 shares. Over the past 30 days that figure has fallen 0.24 percentage points, and over 90 days it has fallen 0.34 percentage points. Its highest recorded short interest was 0.94% in December 2025. OCC is classified in the Pharmaceuticals, Biotechnology & Life Sciences industry. All figures come from official ASIC short position reports, published with a four trading-day (T+4) delay.
Price & short interest
Toggle series, zoom, and compare · ASIC daily, T+4Orthocell (OCC) financials
Results, ratios and statements
Latest result
Year to 30 Jun 2026 (FY26) vs FY25, figures in AUD, the reporting currency
- Revenue
- $11.4Mvs $7.6M (FY25)
- Yahoo Finance, as at 29 Sep 2026
- NPAT
- −$13.9Mvs −$8.6M (FY25)
- Yahoo Finance, as at 29 Sep 2026
- EPS (diluted)
- −$0.053vs −$0.038 (FY25)
- Yahoo Finance, as at 29 Sep 2026
- Rev YoY
- +51.1%FY
- EPS YoY
- n/aTTM
Summary of Appendix 4E & Annual Report, 31 Aug 2026
Orthocell reported full-year revenue of $11.4 million, up 45% from the prior year, while net loss widened 62% to $13.9 million. No dividend was declared. The company did not provide specific guidance for the upcoming period.
Automated summary of the filing; the filing itself is the record.
Key ratios
Year to 30 Jun 2026 (FY); balance sheet at 30 Jun 2026; prices to 9 Oct 2026
- Gross margin
- 100.0%
- Operating margin
- −167.5%
- Net margin
- −122.0%
- FCF margin
- −122.8%
- ROE
- −56.8%
- ROA
- −30.9%
- FCF conversion
- n/a
- Net cash (excl. leases)
- $44.0M
- Net debt / EBITDA
- n/a
- Current ratio
- 6.0×
- Interest cover
- n/a
- Cash dividends paid / net profit
- n/a
- Market cap
- $187.9M
- P/E
- n/a
- P/B
- 5.5×
Ratios use the reporting currency (AUD); market cap is in AUD. Source: Yahoo Finance, as at 29 Sep 2026.
Financial statements
Figures in AUD, the reporting currency; Yahoo Finance unless marked
| Line item | FY26 | FY25 | FY24 | FY23 |
|---|---|---|---|---|
| Revenue | $11.4M | $7.6M | $5.3M | $4.2M |
| Gross profit | $11.4M | $4.8M | $3.7M | $3.2M |
| Operating income | −$19.1M | −$14.0M | −$12.2M | −$10.9M |
| EBITDA | −$18.4M | −$13.4M | −$11.7M | −$10.3M |
| EBIT | −$19.1M | −$14.0M | −$12.2M | −$10.9M |
| Pretax income | −$13.9M | −$11.8M | −$10.2M | −$9.4M |
| Tax | $0 | −$3.2M | −$3.1M | −$3.2M |
| NPAT | −$13.9M | −$8.6M | −$7.2M | −$6.2M |
| Net interest income | $1.8M | $1.2M | $971.2K | $850.8K |
| EPS basic | −$0.053 | −$0.038 | −$0.036 | −$0.032 |
| EPS diluted | −$0.053 | −$0.038 | −$0.036 | −$0.032 |
| Shares | 272.3M | 243.3M | 209.3M | 197.3M |
Financial reports
The company's own filings, newest first
- Appendix 4E & Annual ReportAnnual Results31 Aug 2026via asx_announcements
- Quarterly Activity Report & Appendix 4CQuarterly Report13 Jul 2026via asx_announcements
- Quarterly Activity Report & Appendix 4CQuarterly Report20 Apr 2026via asx_announcements
- Appendix 4D & Half-Year Financial ReportHalf Year Results24 Feb 2026via asx_announcements
- Quarterly Activity Report & Appendix 4CQuarterly Report19 Jan 2026via asx_announcements
- Quarterly Activity Report & Appendix 4CQuarterly Report10 Oct 2025via asx_announcements
- Annual Report to ShareholdersAnnual Report3 Oct 2025via asx_announcements
- Appendix 4E & Annual ReportAnnual Results29 Aug 2025via asx_announcements
- Quarterly Activity Report & Appendix 4CQuarterly Report9 Jul 2025via asx_announcements
- Quarterly Activity Report & Appendix 4CQuarterly Report14 Apr 2025via asx_announcements
Showing 10 of 21 reports